clinical trial · NCT06937229
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Bristol-Myers Squibb·phase3·recruiting·n = 600
Alzheimer DiseaseAgitationKarXTKarX-EC
brief summary
The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who completed the parent studies CN012-0023 or CN012-0024.
started
Dec 2, 2025
primary completion
Jun 22, 2029
completion
Jul 20, 2029
last updated
May 11, 2026
official title
A Phase 3, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-3)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol